Displaying 86 (all) recruiting clinical trials.
-
WUH: "ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)"
?Despite recent improvements in outcome for children with newly diagnosed high-risk neuroblastoma, cure rates remain unsatisfactory. Further, these gains have been the result of interventions ... -
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
The primary purpose of the study is to determine if accelerated BEP (Bleomycin, Etoposide, cisPlatin) is effective and tolerable for patients with advanced gem cell ...
-
Study of inherited monogenic disorders in patient and tissue-specific cells
We propose to collect blood samples to reprogram into patient-specific neuronal, cardiac, and cancer cell lines (see below in the background section) from patients diagnosed ... -
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Low-grade gliomas (LGG) are the most common central nervous system tumor among children, accounting for approximately one-third of pediatric brain tumors. These tumors include a ... -
A single-center observational study of the natural history and pathogenesis of hidradenitis suppurativa
A single-center observational study of the natural history and pathogenesis of hidradenitis suppurativa -
Prospective Multi-Center Pediatric Spine Patient Registry
The goal of this project is to create a registry of children and adults (with disease progression from childhood) with spine and chest wall disorders. -
Site for AAML1831: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
Site for This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with ... -
Gut microbiome alterations as a mechanism of immune dysregulation in new-onset refractory status epilepticus (NORSE)
We will perform a prospective, observational cohort study, with biospecimen collection, of NORSE subjects and subjects with status epilepticus of known cause (e.g. epilepsy ... -
Gut Microbiome in Food Protein-Induced Enterocolitis Syndrome: An Observational Study
Food protein-induced enterocolitis syndrome (FPIES) is a non IgE-mediated food allergy that manifests with predominantly gastrointestinal symptoms and usually starts in the first year of ... -
AALL1732 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
The purpose of the study is to determine the safety and efficiency of the investigational medicine Inotuzumab Ozogamicin for patients who have NCI high risk ...